 CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 GLOBE NEWSWIRE -- Acumen Pharmaceuticals, Inc. NASDAQ: ABOS Acumen, a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease AD, today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights. 